Bio-Path Holdings Inc (NASDAQ:BPTH)’s stock price rose 10.9% during trading on Monday . The company traded as high as $13.34 and last traded at $12.19, approximately 316,600 shares changed hands during trading. A decline of 77% from the average daily volume of 1,361,449 shares. The stock had previously closed at $10.99.
BPTH has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Bio-Path in a report on Friday, August 16th. ValuEngine downgraded shares of Bio-Path from a “buy” rating to a “hold” rating in a report on Friday, October 11th.
The stock has a market capitalization of $32.83 million, a P/E ratio of -0.85 and a beta of 3.21. The firm’s fifty day moving average is $10.56 and its 200-day moving average is $13.69. The company has a current ratio of 18.01, a quick ratio of 18.01 and a debt-to-equity ratio of 0.02.
Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.27). Equities research analysts expect that Bio-Path Holdings Inc will post -3.2 EPS for the current year.
A number of hedge funds have recently made changes to their positions in BPTH. Morgan Stanley lifted its holdings in Bio-Path by 19,858.0% during the 2nd quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after purchasing an additional 19,858 shares during the last quarter. BlackRock Inc. raised its stake in shares of Bio-Path by 17.5% in the second quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock worth $628,000 after acquiring an additional 6,978 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Bio-Path by 10.3% in the second quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock worth $374,000 after acquiring an additional 2,601 shares during the last quarter. 9.48% of the stock is owned by hedge funds and other institutional investors.
Bio-Path Company Profile (NASDAQ:BPTH)
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Story: What is quantitative easing?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.